AVSOLA

This brand name is authorized in United States. It is also authorized in Brazil, Canada, Turkey.

Active ingredients

The drug AVSOLA contains one active pharmaceutical ingredient (API):

1	Infliximab UNII B72HH48FLU - INFLIXIMAB
	Infliximab is a chimeric human-murine monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNFα but not to lymphotoxin α (TNFβ).
	Read more about Infliximab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
AVSOLA Powder for solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AB02	Infliximab	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AB Tumor necrosis factor alpha (TNF-α) inhibitors
Discover more medicines within L04AB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	544121040005507
CA	Health Products and Food Branch	02496933
TR	İlaç ve Tıbbi Cihaz Kurumu	8699862270069
US	FDA, National Drug Code	55513-670